Beam Therapeutics(BEAM) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Key 2024 Anticipated Milestones Beam expects that its cash, cash equivalents and marketable securities as of March 31, 2024, will enable the company to fund its anticipated operating expenses and capital expenditure requirements into 2027. This expectation includes funding directed toward reaching each of the key anticipated milestones for BEAM-101, ESCAPE, BEAM-301 and BEAM-302 described above, as well as continued investments in platform advancements and manufacturing capabilities. Contacts: ...